ABSTRACT
More than a year since the start of the COVID-19 pandemic, the global administration of the COVID-19 vaccines hopes to confer sustained protection against SARS-CoV-2 and stop this difficult to predict situation. They are highly effective, especially at preventing the severe form of disease and reducing the death rate from COVID-19. Pregnant women represent a high-risk category of population for infectious diseases, including COVID-19, and need to be considered for vaccination. Because the results of clinical trials of COVID-19 vaccines in pregnant women are not yet published, many questions remain to be answered. There are now available data and information in real-life data, including healthcare pregnant women or in women who did not know they were pregnant at the time of vaccination. This work aims to present the current state of knowledge about COVID-19 vaccines during pregnancy based on reported cases from medical literature. These cases of COVID-19 vaccination will be more and more, and in the future, we will be supplementarily adding data about the benefits and effects of vaccination on pregnancy, fetal and infant development, and their immunity. Today we affirm: anti-COVID-19 vaccines during pregnancy are reported to be as safe and effective as in the general population. Because a higher rate of miscarriage in early pregnancy has been observed to be associated with COVID-19, it may seem sagacious to recommend vaccination before planning a pregnancy to gain immunity at the time of conception.Copyright © 2021.
ABSTRACT
Background: Influenza is an acute infection affecting all age groups;however, elderly patients are at an increased risk. We aim to describe the clinical characteristics and the circulation of influenza virus types in elderly patients admitted for severe acute respiratory infection (SARI) to a tertiary care hospital in Bucharest, Romania, part of the I-MOVE+ hospital network. Methods: We conducted an active surveillance study at the National Institute for Infectious Diseases “Prof. Dr Matei Balș,” Bucharest, Romania, during three consecutive influenza seasons: 2015/16, 2016/17, and 2017/18. All patients aged 65 and older admitted to our hospital for SARI were tested for influenza by PCR. Results: A total of 349 eligible patients were tested during the study period, and 149 (42.7%) were confirmed with influenza. Most patients, 321 (92.5%) presented at least one underlying condition at the time of hospital admission, the most frequent being cardiovascular disease, 270 (78.3%). The main influenza viral subtype circulating in 2015/16 was A(H1N1)pdm09, followed by A(H3N2) in 2016/17 and B influenza in 2017/18. Case fatality was highest in the 2015/16 season (3.7%), 0% in 2016/17, and 1.0% in 2017/18. Vaccination coverage in elderly patients with SARI from our study population was 22 (6.3%) over the three seasons. Conclusions: Our study has highlighted a high burden of comorbidities in elderly patients presenting with SARI during winter season in Romania. The influenza vaccine coverage rate needs to be substantially increased in the elderly population, through targeted interventions. © 2020 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.